会计年度:2019-06-30收入分布
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 合计 | 9,416,947,166.87 | -- | -- | -- |
| 其他(补充) | 39,039,741.30 | -- | -- | -- |
| 医药工业 | 3,308,183,343.91 | -- | -- | -- |
| 医药商业 | 6,069,724,081.66 | -- | -- | -- |
|
会计年度:2018-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 合计 | 17,989,536,240.19 | 11,477,510,339.77 | 6,512,025,900.42 | 36.20 |
| 化学原料药 | 40,665,131.97 | 24,345,101.02 | 16,320,030.95 | 40.13 |
| 化学制剂药 | 1,499,986,241.43 | 347,114,071.19 | 1,152,872,170.24 | 76.86 |
| 其他(补充) | 84,462,227.96 | 36,488,797.98 | 47,973,429.98 | 56.80 |
| 其中:化学原料药 | 40,665,131.97 | 24,345,101.02 | 16,320,030.95 | 40.13 |
| 其中:化学制剂药 | 1,499,986,241.43 | 347,114,071.19 | 1,152,872,170.24 | 76.86 |
| 其中:生物药 | 227,626,371.79 | 66,675,367.63 | 160,951,004.16 | 70.71 |
| 其中:中药 | 5,358,458,747.30 | 1,306,053,401.09 | 4,052,405,346.21 | 75.63 |
| 生物药 | 227,626,371.79 | 66,675,367.63 | 160,951,004.16 | 70.71 |
| 医药工业 | 7,126,736,492.49 | 1,744,187,940.93 | 5,382,548,551.56 | 75.53 |
| 医药工业小计 | 7,126,736,492.49 | 1,744,187,940.93 | 5,382,548,551.56 | 75.53 |
| 医药商业 | 10,778,337,519.74 | 9,696,833,600.86 | 1,081,503,918.88 | 10.03 |
| 医药商业小计 | 10,778,337,519.74 | 9,696,833,600.86 | 1,081,503,918.88 | 10.03 |
| 中药 | 5,358,458,747.30 | 1,306,053,401.09 | 4,052,405,346.21 | 75.63 |
|
会计年度:2018-06-30
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 合计 | 8,475,946,342.93 | 5,500,413,697.95 | 2,975,532,644.98 | 35.11 |
| 其他(补充) | 39,368,313.60 | 29,821,478.76 | 9,546,834.84 | 24.25 |
| 医药工业 | 3,287,825,760.35 | 837,206,511.12 | 2,450,619,249.23 | 74.54 |
| 医药商业 | 5,148,752,268.98 | 4,633,385,708.07 | 515,366,560.91 | 10.01 |
|
会计年度:2017-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 合计 | 16,020,637,242.44 | 10,217,949,045.47 | 5,802,688,196.97 | 36.22 |
| 化学原料药 | 36,237,046.99 | 25,670,174.91 | 10,566,872.08 | 29.16 |
| 化学制剂药 | 1,309,564,976.94 | 319,945,086.22 | 989,619,890.72 | 75.57 |
| 生物药 | 99,149,550.69 | 52,668,202.67 | 46,481,348.02 | 46.88 |
| 医药工业小计 | 6,814,206,472.54 | 1,774,190,390.81 | 5,040,016,081.73 | 73.96 |
| 医药商业小计 | 9,206,430,769.90 | 8,443,758,654.66 | 762,672,115.24 | 8.28 |
| 中药 | 5,369,254,897.92 | 1,375,906,927.01 | 3,993,347,970.91 | 74.37 |
|
会计年度:2016-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 化学原料药 | 33,269,729.45 | 27,525,309.83 | 5,744,419.62 | 17.27 |
| 化学制剂药 | 1,053,519,321.10 | 261,869,713.55 | 791,649,607.55 | 75.14 |
| 生物药 | 37,912,682.45 | 20,771,050.98 | 17,141,631.47 | 45.21 |
| 医药工业小计 | 6,178,456,917.64 | 1,678,893,906.29 | 4,499,563,011.35 | 72.83 |
| 医药商业小计 | 7,683,569,577.43 | 7,136,544,111.06 | 547,025,466.37 | 7.12 |
| 中药 | 5,053,755,184.64 | 1,368,727,831.93 | 3,685,027,352.71 | 72.92 |
|
2/8 转到 
